Access to medicines: EU must show leadership in fight against chonic diseases

Written by Anthony Gitau on 21 November 2016 in Thought Leader
Thought Leader

The EU must show leadership in the fight against chronic diseases, argues Anthony Gitau.

Anthony Gitau

Anthony Gitau  Photo credit: Novartis


There is a common belief that the pharmaceutical industry is a barrier to access to medicines. As an individual and as a manager working in the industry, I would like to challenge this preconception.

Back in 2000 I was a newly-qualified sales representative. One of the products I was promoting was an antimalarial.

As it happened, I was in a pharmacy in Kenya’s Kisii district talking to a pharmacist about an antimalarial. An old lady came in and handed over a prescription. She looked dismayed when the pharmacist told her the price and said she couldn’t afford the antimalarial which was for her gravely-ill grandson. She headed wearily for the door. I decided to pay for the medicine.


RELATED CONTENT


As an individual, I could help one person but, I knew I couldn’t do it for everyone. In contrast, as an executive in my company, I can work to help increase access to medicines for many more people.

Through the Novartis Access programme, we are delivering affordable medicines to patients affected by non-communicable diseases (NCDs) across Kenya - and we hope to reach 20 million people worldwide by 2020.

In Kenya, no patient should pay more than about US $1.50 per treatment per month.

Peninah is one of those already benefitting from Novartis Access. She lives in Kirinyaga County, close to Mount Kenya. Her children knew that her racing heartbeat and constant headaches were not the normal signs of old age and persuaded her to go to a clinic. The 65-year-old was reluctant at first, but now has her blood pressure in check.

Yet, affordable medicines alone are not enough. Countries need doctors and nurses trained in chronic diseases, with the right equipment to provide diagnoses, and a reliable supply chain to ensure patients have long term access to the treatments they need.

This is why Novartis Access is collaborating with governments and NGOs to overcome these issues and to strengthen healthcare systems.

Recently, we started working with the Kenya Red Cross and faith-based organisations such as the Kenya Conference of Catholic Bishops and the Christian Health Association of Kenya to conduct community and patient awareness campaigns on the ground.

Many people are surprised to learn that NCDs will soon likely kill more Africans than infectious diseases such as HIV, TB and Malaria.

In fact, the World Health Organization estimates that by 2030, the death toll of NCDs will equal that of communicable diseases, maternal and newborn deaths, and malnutrition combined.

I believe there needs to be a concerted effort to support the whole ecosystem around chronic diseases. The European Union’s leadership and focus will hopefully lead to a reprioritisation of NCDs in the national agenda, policy and budgeting of low-and middle-income countries.

About the author

Anthony Gitau is Head of Novartis Access, Kenya

Share this page

Tags

Categories

Partner content

This content is published by the Parliament Magazine on behalf of our partners.

Related Articles

Jerzy Buzek Jerzy Buzek: 2017 should be Europe’s year of Energy Union implementation
10 January 2017

EU has an opportunity to ‘springboard’ the integration of energy policy across several areas, says European Parliament’s energy committee chief

Joseph Muscat Maltese Prime Minister warns EU to prepare for another refugee crisis
18 January 2017

Maltese Prime Minister Joseph Muscat has warned Europe to prepare for another migration crisis.

Related Partner Content

Live animal exports PM+: EU disregarding its own rules on animal exports
31 March 2015

Live animals export trade is marring the EU's reputation as a leader in animal protection, says Olga Kikou.

PM+: Cosmetics animal testing ban under threat
19 May 2015

The EU must ensure that cosmetic ingredients made in Europe are never tested on animals, argues Dr Julia Baines of PETA.

Animal health PM+: Managing the environmental impact of animal pharmaceuticals
11 June 2015

What is the best way to address societal and political concerns about the impact of pharmaceuticals on the environment? IFAH-Europe's...